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Crow deaths were observed after West Nile virus
(WNV) was introduced into North America, and this phe-
nomenon has subsequently been used to monitor the
spread of the virus. To investigate potential differences in
the crow virulence of different WNV strains, American
Crows were inoculated with Old World strains of WNV from
Kenya and Australia (Kunjin) and a North American (NY99)
WNV genotype. Infection of crows with NY99 genotype
resulted in high serum viremia levels and death; the
Kenyan and Kunjin genotypes elicited low viremia levels
and minimal deaths but resulted in the generation of neu-
tralizing antibodies capable of providing 100% protection
from infection with the NY99 strain. These results suggest
that genetic alterations in NY99 WNV are responsible for
the crow-virulent phenotype and that increased replication
of this strain in crows could spread WNV in North America. 
W
est Nile virus (WNV, Flaviviridae:  Flavivirus) is
maintained in nature by transmission between mos-
quitoes and birds and has an extensive geographic range,
including Europe, Africa, the Middle East, southern Asia,
and Australia (1). In 1999, WNV was identified in North
America (2) and has become the leading cause of arbovi-
ral encephalitis in humans and horses (3), as well as hav-
ing been implicated in deaths of members of at least 198
bird species (4). Corvids, including the American Crow
(Corvus brachyrhynchos), appear to be most susceptible
(5,6), and corvid deaths have subsequently been used as a
sentinel to track the spread of the virus (7).
Experimental injection of American Crows with the
North American genotype of WNV (NY99 strain) has con-
firmed its highly pathogenic phenotype. Mean peak
viremia titers in American Crows exceed 9 log10 PFU/mL
in sera, with 100% deaths within 6 days postinfection (dpi)
(5). With the exception of bird deaths in Israel (8), where a
strain 99.8% similar to the NY99 genotype has circulated
since 1997 (9), no bird deaths have been reported during
numerous well-characterized WNV epidemics in North
Africa (10), Europe (11–13), Russia (14), and South Africa
(15). A closely related virus that circulates in Australia
(Kunjin [KUN]) has never been associated with outbreaks
of human or animal diseases, including bird diseases, nor
have bird deaths been reported from enzootic transmission
foci in Africa, where a virus that shares 96.5% nucleotide
identity with the NY99 strain has previously been isolated
(16,17). Possible explanations for the lack of reporting of
bird deaths before 1998 include the following: failure to
identify bird deaths in other regions, a higher susceptibili-
ty to WNV-induced disease among North American birds,
or the fact that the North American WNV strain possesses
increased avian virulence determinants. Additionally, the
possible immunologic cross-protection of birds with lesser
virulent strains could be a factor that has limited the iden-
tification of bird deaths outside the Middle East.
Immunologically naïve bird populations in North America
could be at an increased risk of acquiring severe disease. 
The close genetic relatedness of the North American
WNV genotype with the bird-pathogenic Israeli WNV
strain suggests differential avian pathogenicity among
WNV strains (9). To evaluate whether WNV-associated
deaths in American Crows was due to infection by a more
virulent genotype, we injected American Crows with
NY99, a closely related WNV strain from Kenya (KEN)
and a more distantly related WNV strain from Australia
(KUN) and monitored viremia titers and illness. In addi-
tion, birds that survived challenge with the KEN or KUN
viruses were challenged with a lethal dose of the NY99
strain to assess development of a cross-protective
immunologic response.
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Viral Strains and Birds Used
The lowest passage WNV available were used for crow
virulence studies to avoid incorporating confounding cell-
culture–related genetic substitutions. The NY99 isolate
used was originally isolated from an American Crow brain
(strain NY99-4132) and was subsequently passaged once
in Vero cells before being used for these studies. The
Kenya-3829 (KEN) isolate was made from a pool of male
Culex univittatus mosquitoes (16) and passaged twice in
Vero cells. The Kunjin (KUN-6453) isolate was made
from Cx. annulirostris mosquitoes and was passaged once
in Vero cells and once in hamster kidney cells (Table 1).
After-hatch-year American Crows were obtained by using
net traps with the assistance of the Kansas Department of
Wildlife Resources. The crows were banded and transport-
ed to Fort Collins, Colorado, where they were housed in
the Colorado State University Animal Disease Laboratory
in groups of two in 1-m3 cages. Crows were fed a combi-
nation of ground corn and dried cat food and dog food.  
Detection of Preexisting Flaviviral Antibodies 
To confirm that crows had not previously been exposed
to WNV or another endemic flavivirus, St. Louis
encephalitis virus (SLEV), crows were bled before injec-
tion and serum-tested by plaque reduction neutralization
assays (PRNTs) with WNV and SLEV viruses. Serum was
diluted 1:5, heat inactivated at 56°C for 30 min, and incu-
bated with an equal volume of virus (SLEV; strain TBH-
28) and WNV (strain NY99-4132) to a final concentration
of 100 PFU/0.1 mL. Samples were incubated at 37°C for 1
h, and 0.1 mL of each was added to a confluent monolay-
er of Vero cells in 6-well plates (Costar Inc., Cambridge,
MA). After incubation for 1 h, cell monolayers were over-
laid with 0.5% agarose; a second overlay containing
0.005% neutral red was added 48 h later. Plates were read
1–2 days after addition of the second overlay. A 90%
reduction in PFU, as compared to the serum-negative con-
trol, was used as the determinant of neutralization.
Detection of any neutralizing activity to either SLEV or
WNV within the serum of any crow precluded use for
experimental inoculation.
Virus Injection 
Viral stocks were diluted to 3.2 log10 PFU/0.1 mL in
minimal essential media (MEM) containing no fetal
bovine sera (FBS). One hundred microliters of the diluted
stocks was subcutaneously injected on the breast region of
eight American Crows in four infection groups. Crows
were injected with 1) NY99, 2) KEN, 3) KUN WNVs, or
4) with a media-only injection that served as a virus-nega-
tive control. In addition, a higher dose inoculum of 3.8
log10 PFU/0.1 mL was prepared for injection of a fifth
group of crows with KEN WNV. All crows were examined
for signs of disease twice daily for 14 days after injection
and bled once daily from 1 to 7 dpi for characterization of
viremia. Blood samples were collected from the jugular or
brachial vein by using a 26-gauge needle; 0.2 mL of blood
was added to 0.9 mL of MEM supplemented with 20%
FBS to obtain approximately a 10–1 serum dilution.
Coagulation was allowed to take place at room tempera-
ture for 30 min, at which point samples were placed on ice
and spun at 3,700 x g for 10 min to pellet clotted cells. The
supernatants from these samples were frozen at –80°C
until samples were titrated for infectious units.
Assaying for Infectious Virus 
Infectious virus was assayed by plaque formation on
monolayers of Vero cells. Briefly, serial 10-fold dilutions
of serum were added to Vero cells that were overlaid as
described previously for PRNTs. PFU were enumerated at
3 dpi and multiplied by the dilution factor to determine
viral titers per mL serum. Initial 1:10 dilution of serum as
well as the use of 200 µL of the lowest dilution, resulted in
a limit of viral PFU detection of 1.7 log10 PFU/mL serum.
Inocula for all three viruses were back-titrated by plaque
assay in order to confirm the uniformity of the doses
administered.
Determination of Cross-Protection 
Blood (0.6 mL) was drawn at 14 dpi to determine the
levels of WNV-specific antibodies and cross-neutralization
by using a 2-way β PRNT with homologous and heterolo-
gous WNV strains. Briefly, twofold dilutions of bird serum
samples were incubated at 56°C for 30 min and mixed with
either NY99, KEN, or KUN viruses. Samples were allowed
to incubate for 1 h at 37°C, at which point the samples were
injected onto Vero cells and overlaid as previously
described for PRNT. Plaques were counted, and neutraliza-
tion was reported as a 90% reduction in plaque formation
as compared to the results for the serum-negative control. 
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challenged with 3.2 log10 PFU of NY99 virus from the
same seed that was used for the initial infection of the
experimental NY99 infection group. Crows were bled
daily through 7 dpi and were held through 11 dpi, at which
point an additional 0.6 mL of blood was drawn to assess
modulations in neutralizing activity after secondary chal-
lenge. Serum samples from the seven daily bleedings were
diluted 1:10 in MEM diluent, spun, immediately assayed
for the presence of infectious virus on Vero cells, and then
stored at –80°C. Samples demonstrating virus were thawed
and titrated on Vero cells as described above. Additionally,
serum drawn at the end of the time course was assayed for
antibody by PRNT. 
Statistical Analyses 
Statistical analyses were performed on peak viremia
level, duration of viremia, day of viremia onset, and day of
death. All analyses with the exception of day of death were
performed by analyses of variance (ANOVA). Multiple
comparisons, i.e., confidence intervals (CI) for the differ-
ence of means, were performed by using Tukey’s highest
significant difference (HSD) adjustment for comparisons
of means. Because only two virus groups had birds that
died, the day-of-death comparisons were analyzed by
using a Student t  test with Welch’s modification for
unequal variances. Proportions of illness and death were
compared with the Fisher exact test.
Results
Flaviviral antibodies were not detected in any of the
preinoculation serum samples assayed by PRNT.
Therefore, all captured American Crows were used for
experimental inoculation. Peak viremia titers ranging from
6.7 log10 to10.7 log10 PFU/mL serum (mean peak viremia
titers = 9.2 log10 PFU/mL serum, 95% CI 8.2 log10
PFU/mL serum–10.2 log10 PFU/mL serum) developed in
all crows injected with the NY99 WNV genotype (Figure
1). Onset of viremia occurred within 24 h for three of the
eight crows injected with NY99 and was present in all
eight birds within 48 h postinjection (mean onset of
viremia = 1.8 dpi, 95% CI 1.4 dpi–2.1 dpi) (Table 2). Mean
onset of viremia and mean peak viremia titers differed sig-
nificantly among the virus groups (mean onset, F = 31.6,
df = 3,22, p < 0.001; mean peak viremia, F = 74.9, df =
2,21, p < 0.001). In contrast to the NY99-infected crows,
detectable viremia (>1.7 log10 PFU/mL sera) developed in
two crows infected with the KEN WNV. The onset of
viremia in these two birds was delayed until 3 dpi and 4
dpi, and the mean peak viremia level was lower than that
of the NY99 infection group (7.5 log10 PFU/mL) (differ-
ence of mean onset of viremia = 1.8 dpi, 95% CI 0.4 – 3.1).
When the inoculum dose was increased to 3.8 log10 PFU
for the KEN strain, viremia developed in all eight of the
crows, with peak titers ranging from 4.2 log10 PFU/mL
serum to 6.1 log10 PFU/mL serum (mean = 4.9 log10
PFU/mL serum, 95% CI 4.3–5.4 log10 PFU/mL serum).
The onset of viremia was delayed in the higher dose KEN
group compared to the NY99 infection group (mean = 4.5
dpi, 95% CI 3.9–5.1 dpi; difference of mean onset of
viremia = 2.8 dpi, 95% CI 1.9–3.6 dpi). In all eight crows
inoculated with 3.2 log10 PFU of KUN virus, peak viremia
titers were 2.7–4.9 log10 PFU/mL serum (mean = 4.2 log10
PFU/mL, 95% CI 3.5–4.8 log10 PFU/mL serum). Onset of
viremia relative to the NY99-infected crows was slightly
delayed, with a mean onset at 2.4 dpi (95% CI 1.9–2.8 dpi)
(difference of mean onset of viremia = 0.6 dpi, 95% CI
0.2–1.5 dpi) (Figure 1). Viremia developed in KUN-infect-
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Figure 1. Viremia profiles for West Nile virus (WNV)–infected
American Crows after injection of 1,500 PFU of KUN or KEN/NY99
WNV. Viral titers were determined by plaque formation on Vero
cells and represented as geometric means. A detection limit of
>1.7 log10 PFU/mL crow serum was determined. Bars represent
standard deviations (SD) of the mean. hd, high dose.ed crows, lasting from 1 to 5 days with a mean duration of
3 days (95% CI 1.9–4.1 days). This finding differs qualita-
tively from the NY99- and KEN-infected birds, which sus-
tained viremia for at least 4 days; viremia levels ceased
only when the bleeding time course was halted or at time
of death; the differences between the viremia durations for
the KUN-infected crows and the NY99 and KEN groups
were not statistically significant when adjustments were
made for multiple comparisons.
All crows in the NY99 group died by dpi 6 (Figure 2).
Signs of illness (unresponsiveness, anorexia, weight loss),
signs of encephalitis (shaking, convulsion, ataxia), or both
developed in all NY99-infected crows. In addition, hemor-
rhage from oral and cloacal cavities was evident in five
(62.5%) of the eight crows in the NY99 group. One crow
died of infection with NY99 at 4 dpi, five at 5 dpi, and the
remaining two at 6 dpi (Figure 1). Only one crow (12.5%)
died of infection with the KEN virus with the 3.2 log10
PFU injection. When the dose was increased to 3.8 log10
PFU, 2 (25%) crows did not survive the infection.
Regardless of the dose administered, the crows infected
with the KEN virus demonstrated a reduced mortality rate
(p < 0.001), compared to that of the NY99 virus. Virus was
isolated from the brains of the small subset of crows that
died of infection with the KEN strain (data not shown). In
addition to the three deaths from the KEN WNV genotype,
an additional two crows showed signs of illness, yet sur-
vived through 14 dpi (Table 2). No illness or death was
identified within the KUN infection group, yielding a sig-
nificant difference from the NY99 infection group (p <
0.001), but the KUN group was not statistically differenti-
ated from the KEN WNV infection groups (p = 0.53).
None of the eight crows previously challenged with
KUN virus had detectable illness after secondary chal-
lenge with 3.2 log10 PFU of NY99 virus (Figure 3), which
clearly indicates a cross-protective immune response
against NY99; the lower 95% confidence limit on cross-
protection probability was 0.63. In fact, viremia was not
detected in any of the eight crows rechallenged with the
NY99 WNVon any of the 7 dpi (Figure 4). PRNTs demon-
strated a homologous neutralization response in all eight of
the crows for KUN virus (Table 3). Heterologous titers
against NY99 virus were equal to or only twofold lower
than those against KUN virus. 
Only one of the seven crows from the lower dose (3.2
log10 PFU) KEN WNV inoculation group survived rechal-
lenge with the NY99 strain (Figure 3). Sera drawn before
the NY99 rechallenge from all crows within this group
demonstrated that an immune response had developed in
one crow (the single survivor). This crow demonstrated ill-
ness after the original KEN WNV challenge and was one
of the two crows that had detectable viremia levels and
subsequently exhibited a homologous protective antibody
titer that was indistinguishable from its heterologous titer
against the NY99 virus (1:640) (Table 4). The six KEN-
infected survivors that did not become viremic from the
original KEN viral challenge were devoid of detectable
neutralizing antibody titers and had unmodified infections
after the NY99 challenge. The viremia profile and clinical
outcome (Figures 3 and 4) were indistinguishable from
infection of naïve birds: five crows died on 5 dpi and an
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Figure 2. Survivorship of eight American Crows, each injected with
3.2 log10 PFU of NY99, KEN, or KUN virus. An additional eight
crows were injected with a high dose (hd) of the KEN virus (3.8
log10 PFU). Crows were monitored daily for signs of disease
through 14 dpi. No deaths were found within the control group
(data not shown). additional crow died on 6 dpi. The single surviving crow
that had demonstrated a 1:640 heterologous PRNT titer
against NY99 WNV did not manifest a NY99 viremia
level and had an unmodified 1:640 PRNT titer after the
NY99 challenge. All crows from the group that received
the higher dose of KEN generated KEN viremia titers and
exhibited homologous PRNT titers (1:1,280–2,560) that
were indistinguishable (less than fourfold difference) from
heterologous titers against the NY99 virus. Neither clinical
disease nor NY99 viremia levels were identified in these
crows after secondary challenge with the NY99 virus, but
neutralizing antibody titers increased up to 16-fold. The
rise in PRNT titer was most likely the result of secondary
infection or exposure; however, no control American
Crows (to which a secondary challenge was not adminis-
tered) were assayed for elevated PRNT titers at 24 dpi. 
Sequence analyses of the coding differences between
the NY99 and KEN viruses (Table 5) were performed on a
NY99 virus (that had undergone an additional 2 Vero cell
passages) to assess the possibility that limited cell-culture
propagation could have resulted in attenuating genetic sub-
stitutions found between the KEN and NY99 genotype.
These analyses did not demonstrate any genetic modifica-
tion at any of the KEN or NY99 variable sites, further indi-
cating that the genotype is stable for up to at least 3
passages and that the attenuated phenotype of the KEN or
KUN viruses was unlikely to be the result of an additional
tissue culture passage.
Discussion
Viremia levels observed in these studies confirm previ-
ous observations that American Crows have the potential
to serve as amplification hosts for the NY99 genotype of
WNV but suggest that corvids may not be important hosts
for alternative WNV genotypes because of substantially
reduced viremia titers that would not favor efficient virus
transmission. Furthermore, these results demonstrate that
viral-encoded determinants of avian pathology that are
absent from KEN and KUN viruses exist in the NY99
virus. The viremia levels observed in crows inoculated
with the KEN or KUN viruses were significantly lower
than and delayed in their onset compared to those seen
after inoculation with the NY99 strain. These data demon-
strate that the differential pathogenic phenotypes of the
WNV strains are the result of viral genetic differences that
encode particular virulence determinants. Despite the find-
ing that mouse virulence of the NY99 and KUN WNV
strains (18) correlates well with the virulence phenotype
identified in crow experiments here, experimental infec-
tion of mice with the KEN WNV strain did not demon-
strate an attenuated phenotype (D.W.C. Beasley and
A.D.T. Barrett, pers. comm.). This observation indicates
that differential pathogenic mechanisms could modulate
virulence in disparate vertebrate hosts. 
Elevated viremia level could be a predominant factor
for severe clinical outcome. KUN and KEN WNV-infect-
ed crows in which clinical signs did not develop did not
manifest peak viremia titers >6 log10 PFU/mL; however,
peripheral titers exceeded this level for the three crows in
which neurologic symptoms and death occurred.
Additionally, viremia levels of all crows injected with
NY99 surpassed this level, which suggests that once a
peripheral circulatory threshold titer is achieved, virus is
capable of accessing the nervous system through a non-
specific mechanism. Intracerebral injection of mice with
WNV strains differing in neuroinvasive capacity has
demonstrated uniform lethality, indicating that the ability
to enter the nervous system and not neurovirulence, is
instrumental for virulence of WNV strains (18,19). If this
phenomenon is true for WNV strains in crows, then the
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Figure 3. Survivorship of American Crows previously immunized
with West Nile virus (WNV)-KUN or WNV-KEN viruses after injec-
tion with 1,500 PFU of NY99 WNV. hd, high dose.
Figure 4. Viremia production of American Crows previously immu-
nized with West Nile virus (WNV)-KUN or WNV-KEN viruses after
injection with 3.2 log10 PFU of NY99 WNV. No detectable levels of
viremia (>1.7 log10 PFU/mL crow serum) developed in the KUN
virus-immunized crows (0/8). Data points for the naïve (unexposed
to WNV) crows challenged with the NY99 virus represent the
mean of three samples chosen randomly. Bars represent standard
deviations (SD) of the mean. hd, high dose; PRNT, plaque reduc-
tion neutralization assay.mechanism by which the crow-virulent genotype achieves
extremely high peripheral titers must be elucidated.
Viruses capable of replicating to higher titers could result
from a unique access to cell types that facilitate high-titer
replication through more efficient receptor-envelope inter-
actions, viral replicase differences that increase replication
efficiency within host cells, decreased sensitivity to host
innate immunologic responses, or by altering the physio-
logical host responses such as fever. 
Immunologic status of a host can play an important role
in limiting disease expression. WNV that are capable of
inducing substantial levels of viremia and neuroinvasion of
immunodeficient mice do not necessarily cause viremia or
enter the neural tissues of mice with competent immune
systems (19). Studies have demonstrated that previous
infection with heterologous flaviviruses reduces the inci-
dence of encephalitis and can provide protection from fatal
WNV challenge in a hamster model for WNV pathogenesis
(20,21). In contrast, a neutralization study performed with
WNV strains of different lineages demonstrated that neu-
tralizing antibodies against an Indian WNV strain provided
poor protection against a South African WNV strain (22).
Our results demonstrated that prior immunization with
KUN virus can provide protection from lethal NY99 chal-
lenge in crows. Crows in which a detectable level of
viremia did not develop from the initial KEN viral chal-
lenge exhibited viremia levels and death rates indistin-
guishable from NY99-infected naïve crows. Crows injected
with the higher doses, which led to productive infections
with the KEN virus, produced neutralizing-antibody titers
that were protective against lethal NY99 challenge. The
cross-neutralization of WNV strains suggests that areas in
which WNV virus is endemic could be much less suscepti-
ble to invasion by the crow-virulent NY99 genotype.
The effect that endemic flaviviruses such as SLEV has
on the genetic stability of WNV in North America remains
unclear; however, the fact that WNV and SLEV are distin-
guishable serologically through PRNT (23) and that WNV
activity within the United States has occurred sympatrical-
ly within SLEV transmission foci (3) suggest that SLEV
seroprevalence in birds has little impact on WNV trans-
mission. Previous studies have demonstrated in a flaviviral
pathogenesis hamster model that previous exposure to
SLEV can significantly reduce WNV viral titers (21).
Future experiments are warranted to determine if such pro-
tection is afforded in avian species. 
Experimental inoculation with an Egyptian WNV strain
has demonstrated deaths in sparrows and crows (24), pro-
viding evidence that bird deaths could result from natural
infection with alternative WNV genotypes. Despite this
fact, no bird deaths were reported during a well-described
Egyptian epidemic involving the same viral strain used to
experimentally inoculate these birds (10). Our results
demonstrated that low numbers of deaths can occur from
infection with alternative WNV strains, but the NY99
WNVgenotype is significantly more virulent for American
Crows. This result, coupled with the finding that similar
pathogenicity was identified between the NY99 and KEN
WNV in house sparrows (25), indicates the dual role of
viral pathogenic phenotype and host susceptibility for the
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Differential susceptibility of mouse strains for WNV infec-
tion has been identified and correlated with immunologic
gene expression (26). Future experimental inoculation of
Old World corvids with differential WNV genotypes
would be useful to assess the role that host susceptibility
has on the emergence of WNV genotypes in different geo-
graphic regions. 
The mutations that encode the determinants for differ-
ential crow virulence are currently unknown. In crows
inoculated with a recombinant virus containing WNV
structural genes and nonstructural (NS) genes of yellow
fever virus (YFV), viremia did not develop (27). The fact
that the parental YFV-17D vaccine strain did not replicate
to detectable levels in chickens (28) indicates that flavivi-
ral NS gene regions could modulate viral replication in
birds. Analysis of the complete genomes of the NY99 and
KEN WNV has identified a maximum of 11 amino acids
(Table 5) and 22 nucleotides from the 3'NCR that could
mediate this phenotype (17). Seven (64%) of the 11 amino
acid differences between these viruses resided with the NS
gene region. The close genetic identity between the KEN
and NY99 WNV genotypes makes this an optimal system
for the systematic identification of genetic elements that
encode viral pathogenic determinants. Studies are under
way to identify the specific viral genetic determinants of
crow virulence through the use of infectious cDNAs gen-
erated from both the NY99 and KEN WNV genotypes.
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